Trading update for six months ended 31 July 2026

Inspiration Healthcare Group PLC

08 September 2026

8 September 2026

Inspiration Healthcare Group plc

("Inspiration Healthcare", the "Company" or the "Group")

Trading update for six months ended 31 July 2026

Strong underlying growth across core product portfolio with continued momentum into the second half

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, pioneering specialist neonatal intensive care medical devices, provides a positive trading update for the six months ended 31 July 2026.

Highlights

• Revenues of £22.0 million (H1 FY26: £24.0 million), with strong underlying growth across key product areas

• SLE product revenues of £12.7 million which, excluding the impact of one-off export contracts in the prior year represented underlying growth of 38% in this key division

• Airon revenues increased by 40% to £1.6 million (H1 FY26: £1.1 million)

• MedTech distribution revenues increased by 7% to £7.6 million (H1 FY26: £7.1 million)

• Net debt (excluding IFRS 16 lease liabilities) remained broadly stable at £5.2 million at 31 July 2026 (31 January 2026: £5.1 million)

Revenue for the period was £22.0 million (H1 FY26: £24.0 million) with the prior period benefitting from significant one-off contract revenues of £6.5 million. Against this backdrop, the Group delivered strong underlying growth primarily led by its SLE product portfolio.

Excluding one-off revenues from the prior year, SLE product revenues increased to £12.7 million which represents an increase of 38% over H1 FY26, demonstrating continued demand for the Group's core neonatal intensive care products and further progress towards the strategy to double SLE revenues. Airon also performed strongly in the period, with revenues growing by 40% to £1.6 million following the initial order under the three-year purchasing agreement with a large US healthcare provider.

The Group's MedTech distribution business delivered revenue growth of 7% in the period. As announced on 2 June 2026, the Company is transitioning the distribution of infusion products back to Micrel, with the existing distribution agreement ending on 31 January 2027, enabling the Group to increase focus on its core neonatal business.

Raffi Stepanian, CEO of Inspiration Healthcare Group plc commented: "We are very encouraged by the underlying performance delivered in the first half, which demonstrates the continued progress we are making in building a more sustainable and resilient growth platform. Strong growth in our core SLE portfolio, together with good performances from Airon and MedTech distribution, reflects continued demand for our products and the strength of our position in neonatal intensive care.

"We enter the second half of the year with confidence, a strong orderbook and pipeline of opportunities and expect to close the financial year slightly ahead of market expectations. Our priorities in this period are to convert that pipeline, deliver sustainable profitable growth and continue strengthening the Group's financial position. We believe the progress we are making provides a solid platform for further growth and the creation of long-term shareholder value."

The Company will announce further details of its interim results for the six months ended 31 July 2026 in due course.

For further information:

Inspiration Healthcare Group plc					Tel: +44 (0)20 7496 3000
Raffi Stepanian, Chief Executive Officer
Alan Olby, Chief Financial Officer
Singer Capital Markets (Nominated Adviser & Broker)					Tel: +44 (0)20 7496 3000
Alex Bond Graham Hertrich
Patrick Weaver
Cavendish Capital Markets (Joint Broker)				Tel: + 44 (0)20 7220 0500
Giles Balleny / Joe Smith
Nigel Birks
Harriet Ward
Walbrook PR Ltd (Media & IR)	Tel: +44 (0)20 7933 8780 or inspirationhealthcare@walbrookpr.com
Anna Dunphy			Mob: +44 (0) 7876 741 001
Rachel Broad			Mob: +44 (0) 7747 515 393

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) designs, manufactures and markets pioneering medical technology. Based in the UK, the Company specialises in neonatal intensive care medical devices, which are addressing a critical need to help to save the lives and improve the outcomes of patients, starting with the very first breaths of life.

The Company has a broad portfolio of its own products and complementary distributed products, for use in neonatal intensive care designed to support even the most premature babies throughout their hospital stay. Its own branded products range from highly sophisticated capital equipment such as ventilators for life support through to single-use disposables.

The Company sells its products directly to hospitals and healthcare providers in the UK and Ireland, where it also distributes a range of advanced medical technologies for infusion therapy. In the rest of the world the Company has an established network of distribution partners around the world giving access to more than 75 countries.

The Company operates in the UK from its world-class Manufacturing and Technology Centre in Croydon, South London and in the USA from its facility in Melbourne, Florida.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.